Drug Trial Radar · NCT05370547
Chidamide Bridging for CAR-T Therapy
Last checked: Nov 19, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
May 25, 2022
Primary completion
Jun 30, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The previous research suggests that the low expression of NOXA protein may be an important biomarker for the treatment of drug resistance of chimeric antigen receptor-T (CAR-T) cells. Up regulating the expression of NOXA through histone deacetylase inhibitor (HDACi) can improve drug resistance and significantly improve the therapeutic effect of CAR-T cells. This study will enroll approximately 120 subjects with recurrent or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL). Those with high expression of NOXA will receive conventional CAR-T treatment (without chidamide bridging), and those with low expression of NOXA will be randomly assigned 1:1 to those without or containing chidamide bridging. The purpose of this study was to evaluate the clinical response and safety of chidamide bridging.
Conditions
- Non Hodgkin's Lymphoma
Interventions
ChidamideDrug
1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning. 2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc.
Fludarabine and cyclophosphamideDrug
Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
Anti-CD19 CAR-T cellsBiological
A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with progression-free survival (PFS) at 6 months after CAR-T infusion among all participantsTime frame: 6 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Biotherapeutic Department, Chinese PLA General Hospital
Beijing, China · Recruiting
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Sun Yat-Sen University Cancer Hospital
Guangzhou, Guangzhou, China · Recruiting
Tongji Hospital, Tongji Medical College of HUST
Wuhan, Hubei, China · Recruiting
Xiehe Hospital, Tongji Medical College of HUST
Wuhan, Hubei, China · Recruiting
Tongji Hospital of Tongji University
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Suzhou, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.